Trial Profile

A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab, Administered With Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants With Metastatic Squamous or Nonsquamous Non-Small-Cell Lung Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 28 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pembrolizumab; Pemetrexed
Indications Non-small cell lung cancer
Focus Pharmacokinetics; Registrational
Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

27 Mar 2025 According to a Merck media release, data from time and motion study presented at the European Lung Cancer Congress (ELCC) 2025.
27 Mar 2025 Results published in the Media Release
24 Jan 2023 Planned primary completion date changed from 10 Feb 2023 to 4 Apr 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com